Business Context and Reporting Period
Company: Greatbatch, Inc. (Note: Input metadata referenced "Integer Holdings Corp," but the filing text identifies the registrant as Greatbatch, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and nine months ended September 28, 2007.
Business Overview: Greatbatch operates two segments: Implantable Medical Components (IMC), manufacturing batteries, capacitors, and components for implantable medical devices; and Electrochem Commercial Power (ECP), producing high-performance batteries for commercial applications. The period was characterized by significant M&A activity, including the acquisitions of BIOMEC, Inc. and Enpath Medical, Inc.
Key Financial Metrics
| Metric (in thousands) | Q3 2007 | Q3 2006 | 9M 2007 | 9M 2006 |
|---|---|---|---|---|
| Sales | $79,009 | $69,294 | $234,331 | $207,999 |
| Operating Income | $10,340 | $4,065 | $14,595 | $21,244 |
| Net Income | $5,000 | $3,239 | $12,270 | $14,732 |
| Diluted EPS | $0.22 | $0.15 | $0.54 | $0.65 |
| Operating Margin | 13.1% | 5.9% | 6.2% | 10.2% |
| Net Margin | 6.3% | 4.7% | 5.2% | 7.1% |
| Cash & Equivalents | $95,979 | $71,147 | $95,979 | $71,147 |
| Short-term Investments | $19,774 | $71,416 | $19,774 | $71,416 |
| Total Debt (Convertible Notes) | $240,902 | $170,000 | $240,902 | $170,000 |
| Working Capital | $184,660 | $199,051 | $184,660 | $199,051 |
Cash Flow (Nine Months Ended Sept 28, 2007):
- Operating Activities: $30,842 (in thousands)
- Investing Activities: $(71,169) (in thousands), primarily due to acquisitions.
- Financing Activities: $65,159 (in thousands), driven by debt issuance.
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 14% in Q3 and 13% year-to-date (YTD) compared to 2006. IMC segment sales grew 18% in Q3, driven by ICD capacitors and the inclusion of Enpath Medical sales ($10.0M in Q3). ECP sales were flat in Q3 but up 3% YTD.
- Acquisition Impact: The company acquired BIOMEC (April 2007) and Enpath (June 2007). These transactions resulted in a $16.1 million charge for acquired in-process research and development (IPR&D), which significantly impacted YTD operating income and net income.
- Profitability: While Q3 operating income increased 154% due to lower restructuring costs and higher sales, YTD operating income decreased 31% primarily due to the $16.1M IPR&D charge and increased R&D expenses.
- Debt Structure: In March 2007, the company exchanged $117.8M of existing convertible notes for new notes and issued an additional $80M in convertible notes, increasing total debt to $240.9M. This resulted in a $4.5M gain on extinguishment of debt.
- Restructuring: Ongoing facility consolidations (Carson City, Columbia, Tijuana) and the ECP expansion continued to generate operating expenses, though Q3 expenses were lower than the prior year due to the absence of a $4.4M asset write-off recorded in Q3 2006.
Guidance, Outlook, and Risks
- Outlook: Management expects lower sales volume to continue in Q4 2007 based on updated customer demand forecasts. Organic growth for the year is estimated at 7%. The company anticipates annual cost savings of $2.5M–$3.1M from the Carson City/Tijuana consolidation and $5.0M–$6.0M from the Columbia/Tijuana consolidation once completed.
- Capital Expenditures: Expected capital spending for 2007 is in the range of $20.0M to $35.0M, including the $28M ECP facility expansion.
- Subsequent Acquisitions: Post-period, the company announced agreements to acquire IntelliSensing ($3.9M), Quan Emerteq ($55M), and Engineered Assemblies Corporation ($12M), signaling continued aggressive M&A strategy.
- Tax Rate: The effective tax rate for 2007 is expected to be approximately 48% due to the non-deductibility of a portion of the IPR&D charges. New Mexican tax legislation effective Jan 1, 2008, is under evaluation.
- Risks:
- Customer Concentration: Boston Scientific, Medtronic, and St. Jude Medical collectively accounted for ~67% of sales in the first nine months of 2007.
- Integration Risk: Risks associated with integrating BIOMEC, Enpath, and subsequent acquisitions, including potential distraction of management and failure to realize synergies.
- Legal Proceedings: Enpath is a defendant in a patent infringement lawsuit regarding its FlowGuard valved introducer, which represents approximately 5% of Enpath's revenue. The outcome is uncertain.
- Regulatory: Enpath products are subject to FDA oversight; failure to maintain clearance could impact sales.
Investor Verification Checklist
- Acquisition Integration: Verify the progress of integrating Enpath and BIOMEC operations and the realization of projected cost savings.
- Customer Demand: Monitor Q4 sales trends given management's expectation of lower volume due to customer inventory adjustments.
- Debt Covenants: Confirm compliance with the new credit facility covenants (EBITDA/Interest ratio of 3.00:1 and Leverage ratio of 5.00:1).
- Legal Exposure: Track the status of the patent infringement litigation against Enpath regarding the FlowGuard product.
- Subsequent Acquisitions: Assess the financial impact and integration plans for the three acquisitions announced in October/November 2007 (IntelliSensing, Quan Emerteq, EAC).
- IPR&D Amortization: Review future amortization schedules for the intangible assets acquired, which will impact future earnings.